Publication date: May 01, 2021
Parkinson’s disease (PD) is a movement disorder lacking of validated biomarkers. Experimental studies support the potential value of silent information regulator 1 (SIRT1) in neurodegeneration including PD. We aim to detect the serum levels of SIRT1 in PD patients in order to assess its value as a potential biomarker of PD. Fifty-eight PD patients and 91 healthy controls were included. Serum SIRT1 was determined by enzyme-linked immunosorbent assay (ELISA) and compared between controls and PD patients. Spearman correlation coefficient was analyzed to study the relationship between serum SIRT1 and clinical parameters in PD patients. Receiver operating characteristic (ROC) analysis was conducted to assess the diagnostic value of serum SIRT1 in PD identification. Serum SIRT1 was significantly reduced in PD patients compared with controls. According to the ROC curve, the optimal cut-off point was 0. 47 ng/ml with the sensitivity of 71% and specificity of 71%. Serum SIRT1 level was related to age of onset, disease duration, Hoehn-Yahr staging scale (H-Y stage), Unified Parkinson’s Disease Rating Scale III (UPDRS III), and Mini-Mental State Examination (MMSE). PD patients with cognitive impairment had lower serum SIRT1 than those with normal cognitive ability. Serum SIRT1 was reduced in PD patients and associated with disease severity and cognitive function. Our results indicate that SIRT1 may be a potential biomarker for PD.
|Immunosorbent||Branches of biology|
|Neurodegeneration||PD movement disorder|
|MMSE cognitive impairment|